A multi-epitope-vaccine MEVABC consisting of two linear neutralizing determinants (BC1: aa693-716; A6: aa844-865) located on antigenic unit B/C and unit A of glycoprotein E2 was prepared to evaluate whether a combination strategy is effective in the design of peptide vaccines.After immunization,pig sera collected every one to two weeks were evaluated by enzyme linked immunosorbent assay.C-strain- induced anti-sera and hyper-immune sera cannot recognize overlapping peptides that cover the E2 N-terminus,while MEVABC is able to elicit high levels of peptide-specific antibody response.When compared with previously studied peptide vaccines PV-BC1 and PV-A6,the same dose of either component in the MEVABC increases the BC1- or A6-specific antibodies (to 1/3-1/2 of the levels of the separate vaccines).However,the synergy between the antibodies may make MEVABC much more potent.Moreover,anti-C-strain immunity pre-existing in pigs does not disturb the sequent MEVABC vaccination.Thus,MEVABC can be ad- ministrated to pigs which already possess anti-classical swine fever virus immunity.MEVABC is a promising candidate marker vaccine.